Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Zelira Therapeutics.
RELATED STOCKHEAD STORIES
News
CLOSING BELL: Forcing the product to pay to be the product is about as Meta as it gets
News
CLOSING BELL: ‘We may have gone too far’ says RBA boss poised to push things even further
Health & Biotech
ASX Health Stocks: Zelira to test its own drug against a Big Pharma’s multi-billion dollar revenue star
Explainers
ASX Cannabis Stocks Guide 2022/23: Here’s everything you need to know
News
Market Highlights: Wall Street struggles off the mat, and 5 ASX small caps to watch on Thursday
News
Weekly Small Cap and IPO Wrap: Yes we cannabis; Zelira adds 180% this week, Althea Group up 50%
News
Closing Bell: Somebody told somebody China might want Aussie coal again, willing markets bite
News
Top 10 at 10: Which ASX stocks are getting the stamp of approval today?
News
Closing Bell: Zip abandons Sezzle at altar as ‘sell now, maybe come back later’ trade hits small caps
Health & Biotech
Weed Week: Cannabis lounges in Las Vegas and Cann’s Mildura cannabis facility gets GMP licence
Health & Biotech
Weed Week: Cannabis-feed for chickens and cannabis campaigner nabs Queen’s Birthday honour
News
Market highlights and 5 ASX small caps to watch on Wednesday
Health & Biotech
Could Aussie cannabinoid companies help solve a global opioid crisis?
Health & Biotech
ASX Health Stocks: Invion demonstrates efficacy, Biotron gets feedback from the FDA
Health & Biotech
Weed Week: Woody Harrelson opens weed dispensary and Byron Bay could be home to a cannabis resort
Health & Biotech
ASX Health Stocks: Nyrada gets closer to European patent, and HOPE for Zelira’s autism tincture
News